Claessens, Anouk K. M.
Bos, Monique E. M. M.
Lopez-Yurda, Marta
Bouma, Jeanette M.
Rademaker-Lakhai, Jeany M.
Honkoop, Aafke H.
de Graaf, Hiltje
van Druten, Edith
van Warmerdam, Laurence J. C.
van der Sangen, Maurice J. C.
Tjan-Heijnen, Vivianne C. G.
Erdkamp, Frans L. G. http://orcid.org/0000-0002-4793-4666
,
Funding for this research was provided by:
F. Hoffmann-La Roche
TEVA Nederland B.V.
Article History
Received: 25 July 2018
Accepted: 29 July 2018
First Online: 18 August 2018
Compliance with Ethical Standards
:
: FE has received honoraria from Roche and Novartis and has a consulting/advisory role for these companies. VTH has received honoraria from Pfizer, has a consulting or advisory role for Pfizer, Lilly, and Roche, has received research funding for her institution from Roche, Eisai, Pfizer, and Novartis, and has received travel, accommodations, and/or expenses from Pfizer, Novartis, and Roche. The authors declare that these are considered to be no major conflict of interest.
: The study was registered with EudraCT, number 2010-021519-18, and was conducted according to the International Conference on Harmonization (ICH) and Good Clinical Practice (GCP) guidelines, in agreement with the Declaration of Helsinki (version 1 May 1996) and local regulations (ethics committee Eindhoven, the Netherlands).
: Informed consent was obtained from all individual participants included in the study.
: <b>Data availability</b> Additional data on the trial protocol can be found at the EU Clinical Trials Register, using number 2010-021519-18 (ExternalRef removed). The datasets generated and analyzed during the current study are not publicly available due to ongoing data collection and (future) secondary endpoint analysis. Data, however, are available from the corresponding author on reasonable request.